Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel
OTCMKTS:IPHYF

Innate Pharma 9/17/2026 Earnings Report

Innate Pharma logo
$1.65 0.00 (0.00%)
As of 09/16/2026
Profile

Innate Pharma EPS Results

Actual EPS
N/A
Consensus EPS
-$0.29
Beat/Miss
N/A
One Year Ago EPS
N/A

Innate Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$6.28 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Innate Pharma Announcement Details

Quarter
Date
9/17/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Innate Pharma Earnings Headlines

Sobi partnership with Innate Pharma takes effect
September 17 at 3:10 AM  |  marketscreener.comM
Innate Pharma Secures Sobi Partnership Cash and Extends Runway as Key Oncology Trials Advance
September 17 at 1:51 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/innate-pharma-secures-sobi-partnership-cash-and-extends-runway-as-key-oncology-trials-advance?utm_source=marketbeat.com&utm_medium=referral
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
September 17 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Innate Pharma to deliver H1 2026 business update via investor webcast
September 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/innate-pharma-to-deliver-h1-2026-business-update-via-investor-webcast?utm_source=marketbeat.com&utm_medium=referral
Innate Pharma (IPHYF) Projected to Announce Quarterly Earnings on Thursday
September 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31013638
Innate Pharma to Highlight Oncology Pipeline at H.C. Wainwright Investment Conference
September 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/innate-pharma-to-highlight-oncology-pipeline-at-h-c-wainwright-investment-conference?utm_source=marketbeat.com&utm_medium=referral
See More Innate Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Innate Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innate Pharma and other key companies, straight to your email.

About Innate Pharma

Innate Pharma (OTCMKTS:IPHYF) S.A. is a France-based biotechnology company focused on developing immunotherapies for cancer. The company’s research is centered on the innate immune system, including natural killer cells and other immune mechanisms that can recognize and attack tumor cells. Its activities include drug discovery, clinical development and collaborations with pharmaceutical companies.

Innate Pharma’s pipeline has included antibody-based therapies designed to stimulate or direct immune responses against cancer. Its lead investigational programs have included lacutamab, an antibody being developed for certain T-cell lymphomas, and other oncology candidates targeting immune checkpoints and tumor-associated pathways. The company has also advanced programs through strategic partnerships, including collaborations with AstraZeneca involving monalizumab and other immuno-oncology assets.

Founded in 1999 and headquartered in Marseille, France, Innate Pharma conducts research and development activities in Europe and works with international pharmaceutical partners to advance its therapies. The company’s leadership has included Chief Executive Officer Mondher Mahjoubi, who has guided its development as a clinical-stage immuno-oncology business. Innate Pharma’s shares trade in the United States under the symbol IPHYF.

View Innate Pharma Profile
Earnings Tools